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Abstract: Rhinosinusitis is a significant health problem, causing
significant morbidity and resulting in considerable financial cost.
Some patients suffer persistent or recurrent symptoms despite
receiving optimal medical and surgical treatment. Rhinosinusitis
can be acute or chronic, acute often due to viral or bacterial
infections and chronic which is classified into chronic with nasal
polyposids or chronic rhinosinusitis without nasal polyposis. The
disease affects the quality of life significantly and presents a signif-
icant burden on health costs globally. The anatomical linkage of the
nose with the paranasal sinuses facilitates a common pathology in
both organs. Chronic rhinosinusitis (CRS) has heterogeneous
origins, including viruses, bacteria, fungal infections, anatomical
abnormalities, polyposis, and aspirin sensitivity. Other conditions
such as human immunodeficiency virus acquired immunodeficiency
and cystic fibrosis may also be predisposing factors. Nasal polyposis
is often associated with increased numbers of Th2 lymphocytes,
fibroblasts, goblet cells, mast cells, and eosinophils, with upregula-
tion of IL-13 and the release of specific IgE to staphylococcal
enterotoxins. There is recent evidence that antibiotic treatment may
not be as effective as higher doses of intranasal steroids in acute
uncomplicated rhinosinusitis, especially in those with allergic
disease. The broad inflammatory basis of the pathology of CRS
also reveals a cellular infiltrate theoretically suppressed by intranasal
corticosteroids. This has been confirmed in recent clinical studies of
CRS with or without polyps. A treatment approach based on such
studies reported in the European Position Paper on Rhinosinusitis
guidelines and a guideline summary are presented. The current
review represents the proceedings of a session (3 talks) by the
authors at the first Middle East-Asia Allergy, Asthma, Immunology
Congress in 2009.
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Rhinosinusitis is defined as inflammation of the nose andparanasal sinuses characterized by 2 or more symptoms,
one of which should be either nasal blockage/congestion or
nasal discharge (anterior/posterior nasal drip) and may be
associated with facial pain or pressure and/or a reduction in
smell.1 In addition, there may be either endoscopic signs of
polyps and/or mucopurulent discharge primarily from the
middle meatus and/or edema or mucosal obstruction primarily
in the middle meatus and/or computed tomography changes
showing mucosal thickening within the osteomeatal complex
and/or the sinuses.
Rhinitis usually coexists with sinusitis, and the most
effective diagnostic and management strategies address
both conditions. The disease severity is best assessed using
a 10-point scoring system or visual analogue scale from 0 to
10 and is in this way classified as mild (0–3), moderate
(4–7), and severe (0–10), with a visual analogue scale
of .5 shown to adversely affect a patient’s quality of life.2,3
The disease may also be divided into acute rhinosinu-
sitis (ARS) or chronic rhinosinusitis (CRS). ARS may also
occur recurrently, with the patient not experiencing symptoms
of CRS between the acute episodes. In ARS, patients have
symptoms lasting less than 12 weeks, and the disease remits
completely. ARS may be due to common cold (usually
identified when there is an increase in nasal symptoms after 5
d or persistent symptoms after 10 d but with less than 12-wk
duration). CRS (with or without nasal polyps) is diagnosed
when the patients have symptoms of rhinosinusitis for more
than 12 weeks.
The old nomenclature changed from calling the disease
“sinusitis” to “rhinosinusitis” and is based on the close anat-
omy and continuous mucosae and the fact that the inflamma-
tory pathophysiology usually affects both the sinuses and the
nasal passages. Both organs are lined by pseudostratified co-
lumnar epithelium, and both secrete mucus.
The osteomeatal complex plays a vital role in clearing
mucus produced in the paranasal sinuses, and damage or
inflammation of this complex impairs the normal drainage of
sinus mucus. This typically occurs during a viral infection or
if ciliary function is impaired. If mucus does not flow
normally out of the sinuses, stasis promotes bacterial growth,
resulting in inflammation and infection.
Thus in rhinosinusitis, the inflammatory process affects
the mucosa of the nose and sinuses and may be associated
with mucociliary impairment.4 Rhinosinusitis thus has hetero-
geneous origins, including viruses, bacteria, anatomical
abnormalities, polyposis, aspirin sensitivity (Samter’s triad),
and asthma.
Polyps usually originate in the osteomeatal complex loose
connective tissue and are often eosinophilic. Nasal polyps may
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be classified histologically5 or endoscopically and clinically6
(Table 1). Nasal polyposis is a chronic inflammatory disease
and is characterized by markedly increased numbers of eosino-
phils, Th2-type lymphocytes, fibroblasts, goblet cells, and mast
cells.7,8 Although some patients may also have concurrent aller-
gic rhinitis, the association between ARS and CRS with allergy
has not been clearly defined.7,9 Studies have also demonstrated
a strong local upregulation of IL-13, thymus and activation-
regulated chemokine, and IgE synthesis with the formation of
specific IgE to Staphylococcus aureus enterotoxins, suggesting
a possible role of superantigens in these pathologic processes.10
It is widely believed that most ARS is due to bacterial
infection, and in the United States, rhinosinusitis is the fifth
most common diagnosis for which antibiotics are prescribed,
accounting for 9 and 21% of all pediatric and adult
prescriptions, respectively.1 However, bacteria are only pres-
ent in 60% of ARS cases, which in most cases resolve spon-
taneously.11 The most common bacterial species isolated
include Streptococcus pneumonia, Haemophilus influenzae,
Bacteroides fragilis, and Moraxella catarrhalis, the latter be-
ing more common in children.10 In addition, other conditions
such as cystic fibrosis, primary immunodeficiency, acquired
immunodeficiency syndrome, cigarette smoking, and hypo-
thyroidism may also predispose to ARS or CRS.
The major symptoms of ARS include nasal blockage,
congestion and stuffiness, nasal discharge with postnasal drip,
facial pain, pressure, headache, reduction in smell, and
purulent mucus. Other symptoms may result from laryngeal
and tracheal irritation leading to dysphonia and cough. With
systemic involvement and fever, there may be malaise,
drowsiness, and complications that may occasionally be
serious. ARS is usually treated with antibiotics such as
amoxicillin or penicillin for 10 to 14 days, but while
antibiotics have been reported to cure 82% of cases, 69% of
patients are “cured” with placebo therapy,11,12 and there is
always the risk of developing antibiotic resistance if they are
inappropriately prescribed.
A Cochrane meta-analysis showed a relative risk for cure
of 1.78 (95% confidence interval, 1.00–2.96) for the use of
antibiotic therapy, and there were no improved outcomes seen
with the newer antibiotics, such as cephalosporins, macrolides,
or minocycline compared with penicillins.13 In a study by
Meltzer et al,14 the efficacy and safety of mometasone furoate
nasal spray (MFNS) versus amoxicillin and placebo were stud-
ied in patients with uncomplicated ARS. Rhinosinusitis may be
chronic or may occur recurrently or intermittently.
In this study, 981 subjects older than 12 years were
randomized to receive 200 mg of mometasone once daily or
twice daily for 15 days, 500 mg of amoxicillin 3 times daily
for 10 days, or respective placebo. MFNS twice daily was
significantly superior to placebo (P , 0.001) and amoxicillin
(P # 0.001) at improving symptom score. Global response to
treatment was significantly greater with 200 mg of MFNS
twice daily versus amoxicillin (P ¼ 0.013) and placebo
(P ¼ 0.001). On the other hand, mometasone once daily
was not superior to amoxicillin.14 In addition, treatment with
amoxicillin did not predispose the patients to recurrent dis-
ease. The treatment of uncomplicated ARS with intranasal
steroids thus represents a new paradigm in the clinical treat-
ment approaches now available to clinicians in practice.
In view of the fact that the etiology of CRS is poorly
understood, the role of bacteria is not well defined, and
response to antibiotics is poor, it is necessary to reconsider
carefully the pathology of CRS. Immune responses in CRS are
complex and varied. Tissue eosinophilia may occur in CRS
and shows some relationships to severity, prognosis, and polyp
development. Cellular elements in patients with CRS include
eosinophils/neutrophils, mast cells, macrophages, lymphocytes
and a range of mediators including IL-1, IL-6-IL-8, tumor
necrosis factor-a, IL-3, granulocyte macrophage colony stim-
ulating factor, intercellular adhesion molecule expression-I,
myeloperoxidase and eosinolhilic cationic protein, chemokines
(RANTES and eotaxin) and upregulation of leukotriene recep-
tors.1,2,6,7 Because the production of many of these inflamma-
tory components is downregulated by steroids, steroid therapy
is theoretically an important treatment modality to investigate.
The clinical efficacy of glucocorticoids depends in part on their
ability to reduce airway eosinophil infiltration and to reduce
their viability and activation.15
Current indications for corticosteroids in rhinosinusitis
recommended by the European Position Paper on Rhinosi-
nusitis (EPOS) guidelines3 include the following:
• ARS;
• prophylactic treatment of recurrent ARS;
• CRS without nasal polyps;
• CRS with nasal polyps;
• postoperative treatment of CRS with or without nasal
polyps.
There is increasing evidence that for the treatment of
CRS without polyps, intranasal steroids are beneficial.
Lavigne et al16 investigated the effects of intrasinus
TABLE 1. Classification of Nasal Polyps
Histological
Type 1 Eosinophilic edematous
type
Type 2 Chronic inflammatory
or fibrotic type
Type 3 Seromucinous gland type
Type 4 Atypical stromal type
Clinical and endoscopical
Type 1 Antrochoanal polyps
Type 2 Large isolated polyps





Type 4 Polyps associated with
CRSdeosinophil
dominated
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instillation of budesonide in patients with CRS who were
also allergic and documented a regression of more than
50% of total nasal symptom scores over a 3-week period
with a concomitant reduction in CD31 T cells, eosinophils,
and cells expressing IL-4 and IL-5.
These findings were confirmed in a later study by Lund
et al17 in a double-blind, placebo-controlled, randomized trial
of 134 patients with CRS without nasal polyps treated with
topical intranasal budesonide for 20 weeks. In this study, both
symptom score and peak inspiratory nasal flow were improved.
There is, however, no data showing efficacy of oral
corticosteroids in CRS without nasal polyps. However, the
addition of 400 mg of MFNS twice daily to antibiotics results
in a significantly greater decrease in total symptom score and
individual scores of inflammatory symptoms associated with
obstruction (headache, congestion, and facial pain) compared
with placebo in patients with recurrent rhinosinusitis in a study
published by Meltzer et al.18. For patients with CRS with
nasal polyps, there have been numerous studies on the use
of intranasal and oral steroids.19–23
In a study by Holmberg et al,22 400 mg of fluticasone
propionate and 200 mg of beclomethasone dipropionate (BDP)
were compared with placebo over a 26-week period in a dou-
ble-blind parallel group in patients with bilateral nasal polyps.
There was a significant improvement in symptoms and peak
nasal inspiratory flow for both steroid groups when compared
with placebo, with no statistical differences between the 2
active groups, unrelated to the grade of polyps.
In a study by Keith et al23 using the same dose of
fluticasone dipropionate compared with placebo for 12 weeks,
in 52 patients, polyp reduction was not significant, but nasal
blockage and peak inspiratory flow were significantly
improved in the group treated with intranasal steroids, and
other than a few cases of epistaxis, no other side effects were
reported.
If one considers all the published studies summarized in
the EPOS guidelines on the treatment of CRS without polyps
with corticosteroids,16,17,24–26 4 of the 5 studies showed sig-
nificant improvements, with improvements in maxillary ostial
potency,25 mucociliary clearance,26 airway peak nasal inspi-
ratory flow,17 and effects on T cells, eosinophils, and mes-
senger RNA for IL-4 and IL-5.16 Thus, the overall conclusion
is that steroids given intranasally are of benefit to patients
with CRS without polyps and those with polyps.
Side effects of topical corticosteroids in nasal polyps
are rare. Minor nose bleeding has been reported in some
subjects and is attributed to the vasoconstrictor activity of
corticosteroids. Septal perforation is extremely rare.27 Nasal
biopsy studies have not shown any detrimental structural
effects within the nasal mucosa with long-term administration
of intranasal corticosteroids.28
The systemic bioavailability of intranasal steroids is
variable, and depending on the steroid, potential side effects
include effects on growth, ocular effects, and effects on the
bone and the hypothalamic pituitary adrenal axis. Thus,
steroids such as mometasone furoate and fluticasone furoate,
which have however systemic bioavailability, would be
considered safer, particularly if higher doses are used than
the doses of intranasal steroids used for treating uncompli-
cated allergic rhinitis.
SUMMARY
Rhinosinusitis is a significant health problem, but
published data on CRS are limited, and the disease entity is
still poorly defined, ranging from an expression of the disease
TABLE 2. Treatment and Grade of Recommendation for Adults With ARS (Adapted From Fokkens et al)3
Therapy Grade of Recommendation Relevance
Oral antibiotic A After 5 d or severe cases
Topical corticosteroid A Evidence based
Topical corticosteroid plus oral antibiotic A Evidence based
Oral corticosteroid A For pain reduction in severe disease
Oral antihistamine B Only in allergic patients
Decongestants D As symptomatic relief
Mucolytics, douche phytotherapy D No role
TABLE 3. Treatment and Grade of Recommendation for Adults With CRS With Nasal Polyps (Adapted From Fokkens et al)3
Therapy Grade of Recommendation Relevance
Short-term oral antibiotics ,2 wk D No data
Oral antibiotics .12 wk D No data (possibly for relapse)
Topical antibiotic D No data
Topical steroids A Evidence based
Oral steroids A Evidence based
Decongestant D No data in single use
Mucolytics, antimycotics, immune modulations,
phytotherapy
D No data
Oral antihistamine A In allergic patients
Antileukotrienes C Minimal data
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as discrete acute episodes, which are well defined, to several
different clinical and histological forms of a CRS, in many of
which nasal and sinus polyposis is a significant component.
A summary of the EPOS guidelines for the role of different
treatments for ARS and CRS is given in Tables 2 and 3.29
It is clear from the different pathophysiological findings
of different polyps that the disease is multifunctional and no
single factor can explain the pathogenesis of polyps in CRS;
however, chronic persistent inflammation is undoubtedly
a major factor, irrespective of the etiology.30
Further studies are important to address the optimal
therapy, particularly for recurrent and resistant cases.
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